Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

14.77
+0.72005.12%
Post-market: 14.770.00000.00%19:57 EDT
Volume:2.97M
Turnover:43.62M
Market Cap:1.39B
PE:-4.68
High:14.98
Open:13.88
Low:13.81
Close:14.05
52wk High:15.71
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:0.92
T/O Rate:3.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:13.17
PE(LYR):-4.37

Loading ...

This Biotech Stock is Soaring 132% After Key FDA Vote on Skin Cancer Treatment

Dow Jones
·
Jul 31

Replimune Group Raised to Overweight from Neutral by Cantor Fitzgerald

Dow Jones
·
Jul 31

Top Premarket Gainers

MT Newswires Live
·
Jul 31

Wedbush Upgrades Replimune Group to Outperform From Neutral, Raises Price Target to $12 From $9

MT Newswires Live
·
Jul 31

Replimune Shares Take Flight Premarket After FDA Panel Backs RP1

Dow Jones
·
Jul 31

Replimune Shares More than Double to $11.75 Premarket After US FDA Advisers Back Co's Skin Cancer Drug

THOMSON REUTERS
·
Jul 31

Replimune RP1 Melanoma BLA Wins Favorable 10-3 FDA Advisory Panel Vote on Ignyte Efficacy Data

Reuters
·
Jul 31

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for Rp1 in Advanced Melanoma

THOMSON REUTERS
·
Jul 31

Replimune Group - FDA Target Action Date for Rp1 Bla Resubmission is August 2, 2026

THOMSON REUTERS
·
Jul 31

FDA panel votes 10-3 in favor of Replimune’s experimental melanoma treatment

TIPRANKS
·
Jul 31

FDA Panel Votes in Favor of Replimune's Melanoma Treatment

Dow Jones
·
Jul 31

US FDA Panel Backs Replimune Skin Cancer Drug Study Data

Reuters
·
Jul 31

US FDA Advisers Say Efficacy Results from Replimune’s Skin Cancer Drug Study are Evaluable and Clinically Meaningful

THOMSON REUTERS
·
Jul 31

Veracyte Q2 Revenue Rises on Decipher and Afirma Test Sales

Reuters
·
Jul 31

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Jul 30

Replimune Announces Annual Shareholder Meeting

Reuters
·
Jul 29

U.S. Stocks on the MOVE-Visa, CMS Energy, Ecolab

Reuters
·
Jul 29

BMO sees ‘uphill battle’ for Replimune at Thursday’s FDA panel meeting

TIPRANKS
·
Jul 28

Replimune sinks after FDA briefing documents question RP1 data

TIPRANKS
·
Jul 28

Unusually active option classes on open July 28th

TIPRANKS
·
Jul 28